Medtronic plc (NYSE: MDT), a global leader in healthcare technology, will share new data for the Symplicity Spyral™ renal denervation (RDN) system at the upcoming Cardiovascular Research Technologies (CRT) 2026 annual meeting in Washington, D.C. The conference will showcase safety and efficacy results from the SPYRAL™ HTN Clinical Program, including a late-breaking 36-month pooled analysis of the SPYRAL Clinical Program.

 

Clinical Benefit after Radiofrequency Renal Denervation: Pooled 36-Month Results from the SPYRAL Clinical Program

Late Breaking Presentation | Tuesday, March 10, 8:03 a.m. | International Ball Room Center

Presenter: David Kandzari, M.D.

This late-breaking presentation will report on 3-year results across Medtronic’s SPYRAL Clinical Program, including Global SYMPLICITY Registry (GSR) DEFINE, SPYRAL First-In-Human, SPYRAL HTN-OFF MED, and -ON MED trials.

 

Design and Rationale of the SPYRAL CARE study

Moderated Abstract Presentation | Monday, March 9, 9:03 a.m.  | Innovation Theater

Presenter: Eric Secemsky, M.D.

This moderated abstract presentation will discuss the study design for the SPYRAL CARE study, an observational study of the Medicare population with uncontrolled hypertension treated with either the Symplicity Spyral  RDN System plus standard of care (SOC) or with SOC alone. The SPYRAL CARE Study was simultaneously approved by the U.S. Centers for Medicare & Medicaid Services (CMS) following its final National Coverage Determination (NCD) on renal denervation, the necessary and final piece for an RDN technology to be eligible for coverage for Medicare beneficiaries under the NCD.

 

Radiofrequency renal denervation reduces hypertensive urgencies with potential healthcare cost savings in the United States: two-year pooled analysis of randomized, sham controlled trials 

Moderated Abstract Presentation | Saturday, March 7, 2:46 p.m. | Theater 4

Presenter: Raymond Townsend, M.D.

This moderated abstract presentation will review a pooled analysis of hypertensive emergencies and potential cost savings in the United States over a two-year period for SPYRAL HTN-OFF MED, and -ON MED trials.

The SPYRAL HTN clinical program has the longest and largest real-world registry and the largest dataset showing long-term reductions without the need for additional medication.¹

The Medtronic SPYRAL HTN global clinical program is the most comprehensive clinical program studying RDN in more than 5,000 patients in the presence and absence of medication, and with high baseline cardiovascular risk, and is backed by experience in over 30,000 patients globally.^2-9

The Symplicity Spyral Renal Denervation System is approved for commercial use in 80 countries around the world.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow us on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Kara Hille
Public Relations
+1-763-439-6523

Ingrid Goldberg
Investor Relations
+1-763-505-2696

_{1 Mahfoud F, Mancia G, Schmieder RE, et al. Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE. Hypertension. 2023 Aug ;80(8):1759-177.
2 Medtronic data on file, RDN Catheter Historical Data, Feb 2025. Data includes both Symplicity Flex and Symplicity Spyral.
3 Kandzari DE, Townsend RR, Kario K, et al. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. J Am Coll Cardiol. 2023 Nov 7;82(19):1809-1823.
4 Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020 May 2;395(10234):1444-1451.
5 Kario K, Ogawa H, Okumura K, et al. SYMPLICITY HTN-Japan - first randomized controlled trial of catheter-based renal denervation in asian patients -. Circ J. 2015;79(6):1222–1229.
6 Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial renal denervation for resistant hypertension. N Engl J Med. April 10, 2014;370(15):1393–1401.
7 Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFFMED): a randomised, sham-controlled, proof-of-concept trial. Lancet. November 11, 2017;390(10108):2160–2170.
8 Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–629.
9 Mahfoud F, Schlaich M, Schmieder RE, et al. Long-term outcomes in ESC guideline-recommended patients for RDN from Global SYMPLICITY Registry DEFINE. EuroPCR 2025.}